INSMED Launches Comprehensive Educational Campaign to Raise Awareness of NTM Lung Disease
14 Octobre 2015 - 10:16PM
NTMfacts.com Provides a Dynamic Resource for
Healthcare Providers to Learn More About NTM Lung Disease Through
Patient Testimonials and Case Studies
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the needs of patients with rare diseases today
announced the launch of NTM Facts, an educational campaign designed
to raise awareness of nontuberculous mycobacterial (NTM) lung
disease, a rare and often chronic infection that can lead to
progressive inflammation and lung damage. There are currently no
products indicated for the treatment of NTM lung disease in North
America or Europe. The company’s campaign includes an interactive
website, NTMfacts.com, designed to inform healthcare professionals
about the signs, symptoms, and importance of proper diagnosis of
NTM lung disease, as well as guideline-based options that may help
physicians manage the condition. The launch of the company’s
disease awareness campaign coincides with NTM Week, an American
Thoracic Society (ATS) initiative to recognize rare lung disorders
and foster interaction between patients and clinicians.
NTM lung infections are often difficult to diagnose or
misdiagnosed because symptoms, such as chronic coughing, shortness
of breath, and fatigue, may be similar to other lung conditions. On
NTMfacts.com, healthcare providers can gain first-hand knowledge
from the personal stories of patients who are living with the daily
challenges of chronic NTM lung disease. NTMfacts.com also provides
healthcare providers with a downloadable pocket guide for
diagnosing, treating, and preventing NTM lung disease, which is
based on the official statement of ATS and the Infectious Diseases
Society of America (IDSA) published in 2007.
“Insmed is dedicated to raising awareness of NTM and we
appreciate the importance of connecting physicians with the
experiences of patients who are living with the devastating effects
of this disease,” said Will Lewis, president and chief executive
officer of Insmed. “We look forward to fostering increased
awareness and education as part of our ongoing commitment to
patients and physicians who are faced with numerous clinical
challenges associated with diagnosing and managing NTM lung
disease.”
“It is inspiring to see Insmed’s commitment to raising
physicians’ awareness about the extensive physical and emotional
impact of NTM lung disease,” said Philip Leitman, co-founder and
president of NTM Info and Research, Inc., a non-profit organization
formed on behalf of patients with pulmonary NTM disease. “Raising
NTM awareness will help more patients receive a timely, proper
diagnosis and assist physicians in assessing if treatment should be
initiated to manage symptoms and disease progression.”
About Nontuberculous Mycobacteria Lung
Disease
Nontuberculous mycobacteria (NTM) lung disease is a rare and
often chronic condition that is capable of causing irreversible
lung damage and can be fatal when untreated. The symptoms of NTM
lung disease are variable; however, virtually all patients have
chronic or recurring cough. Other symptoms include sputum
production, shortness of breath, and chest pain. As NTM lung
disease advances, systemic side effects, such as fatigue, malaise,
and weight loss may become increasingly prevalent. NTM lung disease
is caused by organisms commonly found in water and soil and it can
be difficult to diagnose as its symptoms are similar to other
co-existing lung diseases, like bronchiectasis, chronic obstructive
pulmonary disease, cystic fibrosis, and pneumoconiosis.
There are currently no products indicated for the treatment of
NTM lung disease in North America or Europe. Current approaches
usually involve prolonged treatment with multi-drug regimens that
are poorly tolerated with limited effectiveness, especially in
patients with severe disease or in those patients with disease that
is refractory to treatment.
According to a company-sponsored patient chart study,
approximately 50,000 patients suffering from NTM lung disease
visited physician offices in the United States during 2011. A
publication from the National Institutes of Health based on United
States Medicare data from 1997-2007 determined that the annual
prevalence of patients infected with PNTM in the United States
increased 8.2% per year from 20 cases/100,000 to 47 cases/100,000
in people over 65. A 2015 publication from co-authors from several
US government departments stated that prior year statistics led to
a projected 181,037 national annual cases in 2014 costing the US
healthcare system approximately $1.7 billion.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the needs of patients battling serious rare diseases of
high unmet medical need. The company’s current therapeutic areas of
focus include nontuberculous mycobacteria, or NTM, lung disease and
pulmonary arterial hypertension, or PAH. To complement its internal
research and development, Insmed actively seeks in-licensing
opportunities for a broad range of rare diseases. For more
information, visit www.insmed.com.
Contact:
Susan Mesco
Head of Investor Relations
Insmed Incorporated
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024